SCHEMBL664131

SCHEMBL664131

CCOC(=O)[C@H]1CC[C@H](Oc2ccc(C(=O)NCCNC(=O)c3ccccc3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
CHRM5 P08912 3/20 0.52
CHRM2 P08172 1/20 0.52
CHRM3 P20309 1/20 0.52
CHRM1 P11229 2/20 0.50
POLB P06746 2/20 0.50
LMNA P02545 2/20 0.50
CHRM4 P08173 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
OPRM1 P35372 2/20 0.48
OPRD1 P41143 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 2/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL664132 1.00 KDM4E (0.53) KDM4ECHRM5CHRM2CHRM3CHRM1
SCHEMBL10186052 1.00 KDM4E (0.53) KDM4ECHRM5CHRM2CHRM3CHRM1
SCHEMBL10186059 0.92 KDM4E (0.46) KDM4ECHRM5CHRM2CHRM3CHRM1
SCHEMBL10186394 0.92 KDM4E (0.46) KDM4ECHRM5CHRM2CHRM3CHRM1
SCHEMBL663187 0.91 POLB (0.49) KDM4EPOLBLMNAALDH1A1RAB9A
SCHEMBL10184903 0.91 NPC1 (0.56) POLBKMT2AALDH1A1RAB9ANPC1
SCHEMBL10184814 0.91 NPC1 (0.56) POLBKMT2AALDH1A1RAB9ANPC1
SCHEMBL663186 0.91 POLB (0.49) KDM4EPOLBLMNAALDH1A1RAB9A
SCHEMBL10184988 0.91 SMN1; SMN2 (0.54) POLBALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL10184959 0.91 EGFR (0.57) LMNACHRM4MEN1KMT2AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423182-A1 DIACYLETHYLENEDIAMINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-29 EP disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 KDM4E 3060/4885CHRM5 3681/4885CHRM2 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.